Arca
Skip to content
Tools
Tools

IL1R1: Interleukin-1 receptor type 1

Receptor for IL1A, IL1B and IL1RN.

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on IL1R1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 1
  • Other 2

Approved1

  • Anakinra

Phase 30

    Phase 22

    • AMG-108
    • MEDI-8968

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      AnakinraApprovedBiovitrumProtein or peptideAntagonistInterleukin-1 receptor antagonist36
      AMG-108Phase 2AmgenOtherAntagonistInterleukin-1 receptor antagonist0
      MEDI-8968Phase 2MedImmune LLCOtherInhibitorInterleukin-1 receptor inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive TreatmentAnakinraPhase 2Not yet recruitingUniversity Hospital, BrestNov 18, 2026
      Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCTAnakinraPhase 1 / Phase 2Not yet recruitingRuijin HospitalOct 22, 2026
      Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or OlderAnakinraPhase 1Not yet recruitingUniversity of Southern CaliforniaSep 24, 2026
      Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)AnakinraPhase 1Not yet recruitingUniversity of North Carolina, Chapel HillMay 20, 2026
      Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal DiseaseAnakinraPhase 2Not yet recruitingMarc DonathMay 12, 2026
      "IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"AnakinraPhase 1 / Phase 2RecruitingNantes University HospitalMar 31, 2026
      Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic StrokeAnakinraPhase 2RecruitingBeijing Tiantan HospitalFeb 20, 2026
      BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema ReductionAnakinraEarly phase 1Not yet recruitingNorthwestern UniversityFeb 13, 2026

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Ascending aortic dissection0.45
      • CINCA syndrome0.38
      • Immune system disorder0.37
      • Neurodegenerative disease0.35
      • Chronic recurrent multifocal osteomyelitis 30.34
      • Adult-onset Still disease0.33

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1959, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P14778, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.